Barnes Group Inc. - B STOCK NEWS

Barnes Group Inc. (B) announces a quarterly cash dividend of $0.16 per share, payable on March 8, 2024, to shareholders of record as of February 22, 2024, continuing a long history of dividend payments since 1934.

Hexagon's Manufacturing Intelligence division has announced the winners of its third 'Sixth Sense' cohort, Flexxbotics and Zaptic, who will receive resources for global expansion and be showcased on Hexagon's cloud-based digital reality platform. The program aims to identify emerging innovations and provide a platform for high-growth startups, granting them access to resources and customers typically beyond reach at this stage of their development.

GelSight and Hexagon have entered into a global partnership agreement to promote and sell GelSight’s tactile sensing products and future integrated products to the market. The partnership will accelerate the time to market for future products that offer more complete solutions to manufacturing issues. Hexagon’s metrology technologies will complement GelSight’s digital touch technology, offering unique solutions for manufacturing and surface inspection challenges. The partnership also unlocks new applications that digitize manual inspection processes. GelSight CEO will be featured as a speaker at Hexagon’s Sixth Sense event to share about the powerful partnership.

ETQ, part of Hexagon, achieved significant growth in Q4 2023, expanding its customer base globally. New partnerships with Augmentir and Infor strengthen its connected worker strategy. The company was recognized with industry awards and participated in major industry events, showcasing its leading cloud-native solution, ETQ Reliance® NXG.

Integrum (INTEG) announces the sale of OPRA Implant Systems worth SEK 3.5 million to the Center of Excellence in Kyiv, Ukraine, following the successful establishment of the center in December 2023. The company has trained and certified two senior surgeons to perform surgeries on amputees using the innovative implant system. The purchase aims to ensure continuous access to the OPRA Implant System. The disclosure contains information pursuant to the EU Market Abuse Regulation. The CEO, Rickard Brånemark, highlighted the urgent need for amputee care in Ukraine, especially following the Russian invasion. The company's implant system, which attaches directly to the skeleton, provides the best care for many amputees. The PR also includes contact information for more details and the Certified Adviser for Integrum. The press release can be found at the link provided.

Barnes Group Inc. (NYSE: B) has entered into a definitive agreement to sell its Associated Spring™ and Hänggi™ businesses to One Equity Partners for $175 million, aiming to reduce debt incurred from the strategic acquisition of MB Aerospace in August 2023. The expected net cash proceeds of $150 million will help achieve a Net Debt to EBITDA ratio of 3.0x or lower by the end of 2024. The divestiture reflects a leap forward in rationalizing the Industrial business and rebalancing the portfolio toward the Aerospace business, positioning Barnes for success.

BioArctic AB (Nasdaq Stockholm: BIOA B) partner Eisai's Scientific Advisory Group (SAG) to discuss lecanemab's Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) in Q1 2024. Eisai expects European Commission's decision in Q2 2024.

BioArctic AB's (Nasdaq Stockholm: BIOA B) partner Eisai announced that Leqembi has been approved in China as a treatment for mild cognitive impairment and mild AD dementia due to Alzheimer's disease. Leqembi is the first approved treatment shown to reduce the rate of disease progression and slow cognitive and functional decline. The drug is based on the large global Phase 3 Clarity AD study, where it met its primary endpoint and all key secondary endpoints with statistically significant results. Eisai estimates that there are 17 million patients with MCI or mild dementia due to AD in China today, which is expected to increase with the aging of the population. BioArctic has a long-term collaboration with Eisai regarding the development and commercialization for Leqembi. Eisai is responsible for the clinical development, applications for market approval, and commercialization of the drug. BioArctic has no development costs for Leqembi in Alzheimer's disease and is entitled to payments in connection with certain regulatory approvals, and sales milestones as well as royalties on global sales.

ARound (NASDAQ: STGW) collaborates with Immersal to develop a turn-key WebAR solution for stadium AR, aiming to enhance fan engagement and create new avenues for brands to connect with audiences. The partnership marks a significant milestone in bringing innovative AR experiences to live sports and entertainment, with plans to announce their inaugural collaboration with a major sports league next month.